Total Funding
87
68
Total FundingVenture - Series Unknown raised
Growth Score
-3 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
49882
Flow Pharma offers a T-Cell based vaccine delivery platform with 10 issued patents, 24 pending, and 10 published scientific articles.
- Charles Vincent Herst: Chief Science Officer
- Scott Burkholz: VP Business Development
About the Company
Flow Pharma offers a T-Cell based vaccine delivery platform. The vaccine platform has been tested in an HIV vaccine application (Immunity Project program in partnership with Until There’s A Cure) yielding promising results in animals and in human blood. Flow Pharma is now using a similar approach to develop a vaccine for Ebola, Marburg, and triple
negative breast cancer. The company received the first breast cancer collaboration agreement at the largest cancer hospital in Saudi Arabia on 5/11/23. Flow Pharma has 10 issued patents in the US, EU, Canada and Australia and 10 published scientific articles can be found here www.flowpharma.com We are based in Cleveland, Ohio and Riyadh, Saudi Arabia.
